ARX ASX · Health Care

Aroa Biosurgery Ltd

Announcements, last 12 months: 55
Price sensitive, last 12 months: 9
Followed on InvestorPA: High (Among the 5% most-followed companies on InvestorPA)

Latest announcements

Released	Headline	Actions
19 Oct 2026, 9:18 AM	Change in substantial shareholding from AEF
16 Oct 2026, 8:58 AM	Molnlycke to Co-promote Endoform In the US
12 Oct 2026, 4:27 PM	Notification of cessation of securities - ARX
12 Oct 2026, 8:46 AM	Investor Presentation - Symphony RCT
7 Oct 2026, 10:01 AM	Invite to Investor Webinar on Symphony RCT
7 Oct 2026, 8:39 AM	Investor Presentation - MASTRR Interim Analysis
6 Oct 2026, 3:33 PM	Change in substantial holding
5 Oct 2026, 9:36 AM	Symphony Significantly Improves DFU Healing Price sensitive	AI summary
29 Sep 2026, 9:29 AM	Invite to Investor Webinar on MASTRR Interim Analysis
4 Sep 2026, 9:01 AM	Myriad MASTRR Study Reports Low Infection Rates

Sign in to see all ARX announcements.

Guidance history

26 May 2026	Total revenue guidance: NZ$92-100m, FY26 result: NZ$104m; Normalised EBITDA guidance: NZ$5-8m, FY26 result: NZ$11m
26 May 2026	FY27 revenue guidance of NZ$115-125 million, normalized EBITDA of NZ$8-11 million
30 Apr 2026	The company expects total revenue of approximately NZ$104 million on an actual basis (NZ$101 million constant currency), representing growth of 21% (constant currency) on FY25 results. Normalised EBITDA is likely to be in the range of NZ$11-12 million on an actual basis (NZ$10-$11 million constant currency).

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow ARX to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.